Malaria continues to pose a serious global health threat, with rising drug resistance making treatment more difficult. Consequently, Plasmodium yoelii, a rodent malaria parasite, has become an invaluable model for studying the malaria parasite's complex biology, particularly host-parasite interactions and drug resistance mechanisms. Originating from African rodents, P. yoelii presents unique genetic diversity, mirroring critical aspects of human malaria and allowing for detailed research on the parasite's pre-erythrocytic and erythrocytic stages. This review introduces a novel perspective by comprehensively examining P. yoelii from multiple angles, including its origin, genetic composition, and contributions to vaccine development and drug efficacy studies. It highlights the significance of P. yoelii, revealing new insights into immune evasion, pathogenesis, and disease severity, which are critical for developing future malaria interventions. Furthermore, this review addresses the challenges associated with P. yoelii as a model, such as differences in host immune responses between rodents and humans. Despite these hurdles, the research using P. yoelii offers promising directions for combating malaria. This novel synthesis of P. yoelii studies underscores its essential role in advancing malaria research, particularly in understanding drug resistance and uncovering potential therapeutic and vaccine targets.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799112 | PMC |
http://dx.doi.org/10.1007/s11033-025-10318-4 | DOI Listing |
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFACS Appl Bio Mater
March 2025
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow 226025, India.
Multidrug resistance (MDR) infectious wounds are a major concern due to drug resistance, leading to increased patient morbidity. Lichenysin (LCN), a lipopeptide and biosurfactant obtained from certain strains of , has demonstrated an excellent antimicrobial property. The present study focuses on the fabrication and comprehensive evaluation of LCN-incorporated poly(vinyl alcohol) (PVA)/polycaprolactone (PCL)-based nanofiber scaffolds using an electrospinning technique as a potential wound healing biomaterial for the treatment of MDR infectious wounds in diabetic rats.
View Article and Find Full Text PDFJ Appl Microbiol
March 2025
Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, P.O.Box 9086, Addis Ababa, Ethiopia.
Aims: Mycobacterium tuberculosis (Mtb) remains a major global health challenge, particularly due to increasing drug resistance. Beyond the well-characterized mutations, the mechanisms involved in driving resistance appear to be more complex. This study investigated the differential gene expression of Ethiopian drug-resistant Mtb sub-lineage 4.
View Article and Find Full Text PDFJ Genet Eng Biotechnol
March 2025
State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, China; Department of Hepatobiliary and Echinococcosis Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China. Electronic address:
Background: Few studies revealed that stromal genes regulate the tumor microenvironment (TME). However, identification of key-risk genes in the invasive ductal breast carcinoma-associated stroma (IDBCS) and their associations with the prediction of risk group remains lacking.
Methods: This study used the GSE9014, GSE10797, GSE8977, GSE33692, and TGGA BRCA datasets.
Endocr J
March 2025
Hypothalamic & Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan.
The 2017 World Health Organization classification described aggressive pituitary neuroendocrine tumor (PitNET) as "a tumor with strong invasiveness and rapid growth, which is difficult to treat with surgery, radiation therapy, or drug therapy," which remains a challenge in the treatment of pituitary tumors. Currently, temozolomide (TMZ) is the first-line treatment for aggressive PitNET. However, it is not yet covered by insurance in Japan.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!